BrainStorm's Cell Therapy Disappoints In Phase III ALS Study
But Subgroup Analysis Encouraging
Top-line results from BrainStorm’s NurOwn Phase III ALS study show the cell therapy missed the primary efficacy endpoint, but clinically meaningful responses were seen in a pre-specified subgroup which investigators considered potentially a significant step forward in therapy.
